| Dr Christopher A Cox, MD | |
|
1800 Harrison St Fl 7, Oakland, CA 94612-3466 | |
| (925) 295-4000 | |
| Not Available |
| Full Name | Dr Christopher A Cox |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 18 Years |
| Location | 1800 Harrison St Fl 7, Oakland, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013104215 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital - Walnut Creek | Walnut creek, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Permanente Medical Group Inc | 8921910225 | 7800 |
News Archive
SHEFFIELD Teaching Hospitals NHS Foundation Trust has become the first NHS hospital in the UK to start offering its patients a new non-invasive treatment for wet age-related macular degeneration (wet AMD).
Although there is no one established universal cause of cancer, genetic changes are central to its development. The accumulation of spontaneous genetic changes, or mutations, that occur when cells divide can be hastened by exposure to carcinogens such as cigarette smoke (lung cancer) and infectious agents such as the papillomavirus (cervical cancer).
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and Aurigene Discovery Technologies Ltd., a Bangalore based fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre IND drug candidates, today announced the successful nomination of a development candidate, Debio 0617, a novel inhibitor of an undisclosed oncology pathway.
A new study, released as a preprint on the bioRxiv* server, describes the late-stage clinical trial efficacy of a new vaccine candidate based on a deoxyribonucleic acid (DNA) plasmid platform expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Among different constructs of the vaccine plasmid, the RBD was found to produce the most potent and broad immune response.
› Verified 3 days ago
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
SHEFFIELD Teaching Hospitals NHS Foundation Trust has become the first NHS hospital in the UK to start offering its patients a new non-invasive treatment for wet age-related macular degeneration (wet AMD).
Although there is no one established universal cause of cancer, genetic changes are central to its development. The accumulation of spontaneous genetic changes, or mutations, that occur when cells divide can be hastened by exposure to carcinogens such as cigarette smoke (lung cancer) and infectious agents such as the papillomavirus (cervical cancer).
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and Aurigene Discovery Technologies Ltd., a Bangalore based fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre IND drug candidates, today announced the successful nomination of a development candidate, Debio 0617, a novel inhibitor of an undisclosed oncology pathway.
A new study, released as a preprint on the bioRxiv* server, describes the late-stage clinical trial efficacy of a new vaccine candidate based on a deoxyribonucleic acid (DNA) plasmid platform expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Among different constructs of the vaccine plasmid, the RBD was found to produce the most potent and broad immune response.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher A Cox, MD 1800 Harrison St Fl 7, Oakland, CA 94612-3466 Ph: (925) 295-4000 | Dr Christopher A Cox, MD 1800 Harrison St Fl 7, Oakland, CA 94612-3466 Ph: (925) 295-4000 |
News Archive
SHEFFIELD Teaching Hospitals NHS Foundation Trust has become the first NHS hospital in the UK to start offering its patients a new non-invasive treatment for wet age-related macular degeneration (wet AMD).
Although there is no one established universal cause of cancer, genetic changes are central to its development. The accumulation of spontaneous genetic changes, or mutations, that occur when cells divide can be hastened by exposure to carcinogens such as cigarette smoke (lung cancer) and infectious agents such as the papillomavirus (cervical cancer).
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and Aurigene Discovery Technologies Ltd., a Bangalore based fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre IND drug candidates, today announced the successful nomination of a development candidate, Debio 0617, a novel inhibitor of an undisclosed oncology pathway.
A new study, released as a preprint on the bioRxiv* server, describes the late-stage clinical trial efficacy of a new vaccine candidate based on a deoxyribonucleic acid (DNA) plasmid platform expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Among different constructs of the vaccine plasmid, the RBD was found to produce the most potent and broad immune response.
› Verified 3 days ago
George A. Pugh, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 80 Grand Ave Fl 5, Oakland, CA 94612 Phone: 510-451-6266 Fax: 510-451-6260 | |
Austin Arlo Pitcher, MD, PHD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3315 Broadway, Oakland, CA 94611 Phone: 925-939-8585 | |
Dr. James Lyman Shively, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 747 52nd St, Oakland, CA 94609 Phone: 510-428-3000 | |
Dr. Eric O. Eisemon, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 275 W Macarthur Blvd, Oakland, CA 94611 Phone: 510-752-1000 | |
Dr. Wayne Pan, MD, PHD, MBA Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 5901 Vallejo St Apt D, Oakland, CA 94608 Phone: 650-922-8131 | |
Jeffrey A. Mann, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 350 30th St Ste 530, Oakland, CA 94609 Phone: 510-422-5150 Fax: 510-422-5149 |